Analysts Set Expectations for RNAC FY2025 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Cartesian Therapeutics in a research report issued on Monday, March 17th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn ($3.65) per share for the year. Cantor Fitzgerald has a “Hold” rating on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is $4.56 per share.

Other equities analysts have also recently issued research reports about the stock. BTIG Research started coverage on shares of Cartesian Therapeutics in a research note on Thursday, December 19th. They set a “buy” rating and a $42.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $41.00 target price on shares of Cartesian Therapeutics in a research note on Thursday, March 13th. Finally, HC Wainwright lowered their target price on shares of Cartesian Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $42.14.

Cartesian Therapeutics Stock Performance

RNAC opened at $14.60 on Wednesday. The stock has a market capitalization of $378.24 million, a P/E ratio of -0.28 and a beta of 0.71. The company’s 50-day simple moving average is $18.46 and its two-hundred day simple moving average is $18.76. Cartesian Therapeutics has a 52-week low of $11.67 and a 52-week high of $41.87.

Insider Activity

In related news, CTO Metin Kurtoglu sold 2,458 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $16.83, for a total value of $41,368.14. Following the completion of the sale, the chief technology officer now directly owns 62,258 shares of the company’s stock, valued at approximately $1,047,802.14. This represents a 3.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Blaine Davis sold 3,961 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $16.72, for a total transaction of $66,227.92. Following the completion of the sale, the chief financial officer now directly owns 98,839 shares of the company’s stock, valued at $1,652,588.08. This represents a 3.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,744 shares of company stock valued at $247,337 in the last quarter. 57.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cartesian Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MPM Bioimpact LLC increased its holdings in Cartesian Therapeutics by 14.6% in the 4th quarter. MPM Bioimpact LLC now owns 721,139 shares of the company’s stock worth $12,916,000 after acquiring an additional 91,716 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in Cartesian Therapeutics by 197.8% in the 4th quarter. Nuveen Asset Management LLC now owns 72,099 shares of the company’s stock worth $1,291,000 after acquiring an additional 47,889 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Cartesian Therapeutics by 44.8% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,786 shares of the company’s stock worth $104,000 after acquiring an additional 1,789 shares in the last quarter. Bank of America Corp DE grew its holdings in Cartesian Therapeutics by 54.4% during the 4th quarter. Bank of America Corp DE now owns 11,690 shares of the company’s stock valued at $209,000 after buying an additional 4,120 shares in the last quarter. Finally, 683 Capital Management LLC grew its holdings in Cartesian Therapeutics by 65.7% during the 4th quarter. 683 Capital Management LLC now owns 125,000 shares of the company’s stock valued at $2,239,000 after buying an additional 49,569 shares in the last quarter. 86.95% of the stock is owned by hedge funds and other institutional investors.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.